and support of these patients will increase (Vella, B., 2002). The most modern diagnostic
methodology does not point to any test, any biologic marker, or any method that
improves the diagnosis of AD in the early or in the middle phases of the disease
(Sanchez, J.L., and Sayago, A.M., 2000). This research protocol will try to find out a
clinically useful diagnostic method that can be applied to the population in general as a
screening test to predict onset or to detect early stage incidence of AD, so that early
therapy can slow the progression of the disease. It is increasingly being recognized that
interventions in AD are most efficacious if applied early in the course of the disease
(Nordberg, A., 2003).
Literature Review: Most of the modern and emerging therapies of AD are
dependent on early detection of the disease. These modalities of therapy are less
effective late in the course of well-established disease. Early diagnosis has the
advantages of early pharmacotherapy and detection of dementia when it is mild. Most
often conditions with dementia call for management directed towards both the patients
and their families so that nonpharmacologic interventions directed to both the patient and
the family help them cope up better with the distress of a disease that needs to be endured
in the present status of available therapies (Chang, C.Y. and Silverman, D.H., 2004). The
current approach of diagnosing AD depending on recognition of characteristic clinical
features is largely dependent on examiner's expertise. This reduces the specificity and
sensitivity of the method (Kohler, J. et al., 2002). In the present state of fact a laboratory
diagnosis based on a biologic marker that is salient in...
Differential Diagnosis Of Alzheimer Disease With Cerebrospinal Fluid Levels Of Tau Protein Phosphorylated At Threonine 231, Arch Neurol; 59: pp. 1267 - 1272.
De La Monte, S.M. and Wands, J.R., (1994). Diagnostic Utility of Quantitating Neurofilament -immunoreactive Alzheimer's Disease Lesions, The Journal of Histochemistry and Cytochemistry, Vol. 42. NO. 12, pp. 1627-1634.
De La Monte, S.M. and Wands, J.R., (1994). Diagnostic Utility of Quantitating Neurofilament -immunoreactive Alzheimer's Disease Lesions, The Journal of Histochemistry and Cytochemistry, Vol. 42. NO. 12, pp. 1625-1634.
Kohler, J., Riepe, M.W., Jendroska, K., Pilartz, H., Adler, G., Berger, F.M., Calabrese, P., Frolich, L., Gertz, H.J., Hampel, H., Haupt, M., Mielke, R ., Paulus, H.J., and Zedlick, D., (2002). Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office, Fortschr Med Orig; 120(4): pp. 135-41.
Lopez, O. L., Swihart, A. A., Becker, J. T., Reinmuth, O. M., Reynolds, C. F., III, Rezek, D. L. and Daly, F. L., III, (1990), Reliability Of NINCDS-ADRDA Clinical Criteria For The Diagnosis Of Alzheimer's Disease, Neurology; 40: 1517.
Tapiola, T., Lehtovirta, M., Ramberg, J., Helisalmi, S., L